The market has been down on Cleveland BioLabs, Inc. (CBLI) stock recently. CBLI gets a Bearish score from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With CBLI Stock Today?
Cleveland BioLabs, Inc. (CBLI) stock is trading at $1.50 as of 10:03 AM on Tuesday, Jun 9, an increase of $0.04, or 3.1% from the previous closing price of $1.45. The stock has traded between $1.49 and $1.55 so far today. Volume today is low. So far 92,653 shares have traded compared to average volume of 253,890 shares.
To screen for more stocks like Cleveland BioLabs, Inc. click here.
More About Cleveland BioLabs, Inc.
Cleveland BioLabs Inc is a biopharmaceutical company. The company is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of Toll-like immune receptor activators has applications in the mitigation of radiation injury and immuno-oncology. Its lead product candidate is entolimod, an immuno-stimulatory agent, which is developed as a radiation countermeasure and immunotherapy for oncology and other indications. Entolimod is a Toll-like receptor 5 (TLR5) agonist, which is developed as a radiation countermeasure for prevention of death from Acute Radiation Syndrome (ARS), and as an oncology drug.
